Health Ministry Halts Use of Specific Similac Batch in Hospitals
Translated & summarized from i24NEWS by baba
Israel's Ministry of Health has temporarily stopped the use of a specific batch of Similac formula in hospitals due to a single complaint. The manufacturer, Abbott, is providing an alternative batch while an investigation is underway, with no current safety concerns identified.
The story in 5 lines · by baba
- Health Ministry halts use of Similac batch 89203N201 in hospitals.
- The batch is hospital-exclusive, not sold in retail.
- Decision follows a single complaint, no health effects reported.
- Manufacturer Abbott is supplying an alternative batch.
- No safety concerns identified; use remains suspended pending investigation.
Israel's Ministry of Health announced on Sunday a temporary halt to the use of a specific batch of Similac formula intended exclusively for hospitals. This batch, identified as 89203N201 (stamped on the bottom of the bottle), is not available for retail sale.
The decision was made as a precautionary measure following a single complaint received Saturday evening regarding the hospital-specific Similac product. The ministry emphasized that this is an isolated incident with no reports of adverse health effects associated with the formula.
Abbott, the manufacturer, is working to supply an alternative batch to hospitals. The directive applies only to this particular batch, and other Similac batches are unaffected. Abbott clarified that it is not initiating a voluntary recall of the product but is cooperating with the Ministry of Health on the single complaint.
Currently, no safety concerns regarding the product have been identified, and the temporary suspension of use will remain in effect until the investigation is complete.
